The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation. Authorized by Congress in the FDA Reauthorization Act of 2017, the designation provides certain incentives for industry to develop generics for drugs lacking competition. FDA Commissioner Scott Gottlieb, M.D., said the agency also will advance additional policies over the next year to promote generic competition. “This will include the publication of a series of guidances to address regulatory and scientific challenges that make it generally more difficult to develop complex generics,” he said. “As part of this, we intend to issue draft guidance with recommendations on establishing active ingredient sameness. In addition, we’ll advance the development of new analytical tools and in vitro tests to provide additional accurate, sensitive and reproducible tools to support approval of complex generic drugs.”

Related News Articles

Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported…
Headline
The Senate Finance Committee held on Tuesday the third in a series of hearings on drug pricing in America, which focused on the role of pharmacy benefit…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held the
Headline
A Department of Health and Human Services’ Office of Inspector General proposal to change drug discount safe harbors under the federal anti-kickback statute…
Headline
The House Committee on Energy and Commerce yesterday passed a number of AHA-supported bills that would lower prescription drug costs and strengthen the…